Free Trial

MEDIFAST (MED) Competitors

MEDIFAST logo
$13.28 +0.02 (+0.14%)
Closing price 03:58 PM Eastern
Extended Trading
$13.27 -0.01 (-0.07%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MED vs. LW, NOMD, NUS, USNA, NATR, VERU, EL, PBH, IPAR, and HLF

Should you be buying MEDIFAST stock or one of its competitors? The main competitors of MEDIFAST include Lamb Weston (LW), Nomad Foods (NOMD), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Nature's Sunshine Products (NATR), Veru (VERU), Estee Lauder Companies (EL), Prestige Consumer Healthcare (PBH), Interparfums (IPAR), and Herbalife (HLF).

MEDIFAST vs. Its Competitors

Medifast (NYSE:MED) and Lamb Weston (NYSE:LW) are both consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Lamb Weston had 2 more articles in the media than Medifast. MarketBeat recorded 5 mentions for Lamb Weston and 3 mentions for Medifast. Medifast's average media sentiment score of 0.45 beat Lamb Weston's score of 0.43 indicating that Medifast is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medifast
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lamb Weston
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medifast presently has a consensus price target of $16.50, indicating a potential upside of 24.26%. Lamb Weston has a consensus price target of $65.70, indicating a potential upside of 2.33%. Given Medifast's higher probable upside, equities research analysts clearly believe Medifast is more favorable than Lamb Weston.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Lamb Weston
1 Sell rating(s)
8 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.23

Medifast has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Lamb Weston has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.

Lamb Weston has higher revenue and earnings than Medifast. Lamb Weston is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$602.46M0.24$2.09M$0.3241.50
Lamb Weston$6.45B1.39$357.20M$2.0930.72

95.5% of Medifast shares are held by institutional investors. Comparatively, 89.6% of Lamb Weston shares are held by institutional investors. 2.9% of Medifast shares are held by company insiders. Comparatively, 0.3% of Lamb Weston shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lamb Weston has a net margin of 4.56% compared to Medifast's net margin of 0.76%. Lamb Weston's return on equity of 28.08% beat Medifast's return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast0.76% 2.00% 1.50%
Lamb Weston 4.56%28.08%6.47%

Summary

Lamb Weston beats Medifast on 10 of the 16 factors compared between the two stocks.

Get MEDIFAST News Delivered to You Automatically

Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MED vs. The Competition

MetricMedifastFOOD IndustryStaples SectorNYSE Exchange
Market Cap$145.94M$8.08B$15.68B$21.83B
Dividend YieldN/A3.92%3.26%3.67%
P/E Ratio41.5022.6317.6329.93
Price / Sales0.242.0948.0691.78
Price / Cash4.5212.5214.3717.79
Price / Book0.693.637.104.69
Net Income$2.09M$395.13M$678.09M$1.01B
7 Day Performance-3.98%-0.26%-0.85%0.13%
1 Month Performance-5.01%1.11%-1.25%1.50%
1 Year Performance-23.46%1.36%-1.55%14.25%

MEDIFAST Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MED
MEDIFAST
3.4499 of 5 stars
$13.28
+0.1%
$16.50
+24.3%
-26.4%$145.74M$602.46M41.50870
LW
Lamb Weston
4.3871 of 5 stars
$63.39
+0.8%
$65.70
+3.6%
-10.5%$8.77B$6.45B30.3310,100
NOMD
Nomad Foods
4.8078 of 5 stars
$12.79
-2.3%
$19.75
+54.4%
-31.3%$2.01B$3.35B8.767,788
NUS
Nu Skin Enterprises
3.629 of 5 stars
$11.47
+0.9%
$6.88
-40.1%
+67.1%$562.79M$1.73B5.713,100Analyst Upgrade
USNA
USANA Health Sciences
4.6961 of 5 stars
$26.61
-2.0%
$36.00
+35.3%
-42.5%$496.26M$854.50M14.781,700News Coverage
Earnings Report
Upcoming Earnings
Analyst Downgrade
Analyst Revision
NATR
Nature's Sunshine Products
3.7112 of 5 stars
$15.20
-2.0%
$20.50
+34.9%
+11.6%$273.53M$454.36M20.54850News Coverage
Positive News
VERU
Veru
2.4231 of 5 stars
$4.01
+5.5%
$33.33
+731.3%
-52.2%$55.70M$16.89M-1.82230
EL
Estee Lauder Companies
3.9463 of 5 stars
$88.67
+0.7%
$88.55
-0.1%
-3.7%$31.68B$14.33B-28.2457,000News Coverage
Analyst Upgrade
PBH
Prestige Consumer Healthcare
4.4256 of 5 stars
$63.26
-1.1%
$94.80
+49.9%
-11.1%$3.15B$1.14B14.85540Analyst Forecast
IPAR
Interparfums
4.2115 of 5 stars
$93.41
-1.2%
$162.00
+73.4%
-25.5%$3.04B$1.45B18.72530
HLF
Herbalife
3.9424 of 5 stars
$8.83
+2.0%
$11.50
+30.2%
+24.9%$892.90M$4.99B2.798,600News Coverage

Related Companies and Tools


This page (NYSE:MED) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners